TCT

This channel contains news about the annual Transcatheter Cardiovascular Therapeutics (TCT) conference presented by the Cardiovascular Research Foundation (CRF). It includes coverage from the annual meeting and links CRF news. TCT is the premier conference for the subspecialty of interventional cardiology, including the new subspecialty areas of transcatheter structural heart procedures. 

Gore Cardioform ASD Occluder Receives FDA Approval
Technology | Structural Heart Occluders | June 10, 2019
June 10, 2019 – W. L. Gore & Associates (Gore) announced the U.S. Food and Drug Administration’s (FDA’s) premarket...
Cordis Announces U.S. Launch of Radial 360 Portfolio
Technology | Radial Access | May 15, 2019
May 15, 2019 — Cordis, a Cardinal Health company, recently announced the full U.S. launch of its Radial 360 portfolio,...
Boston Scientific Receives FDA Approval for Lotus Edge Aortic Valve System
Feature | Heart Valve Technology | April 23, 2019 | Dave Fornell, Editor
April 23, 2019 — The U.S. Food and Drug Administration (FDA) has cleared the Boston Scientific Lotus Edge transcatheter...
FDA Approves MitraClip for Use in Heart Failure Patients With Functional Mitral Regurgitation
Feature | Heart Valve Technology | March 14, 2019 | Jeff Zagoudis, Associate Editor
March 14, 2019 — The U.S. Food and Drug Administration (FDA) approved the MitraClip heart valve repair device for...

A comparison of stent strut thickness between the Orsiro stent, pictured, and the market-leading stents on the U.S. and European markets. Vendors have been working toward reducing strut thickness to help improve overall clinical outcomes. Orsiro is now the smallest strut stent available on the market. 

Feature | Stents | February 22, 2019 | Dave Fornell, Editor
February 22, 2019 — The U.S. Food and Drug Administration (FDA) has approved the Biotronik Orsiro drug-eluting stent (...
The Boston Scientific Eluvia self-expanding, drug-eluting peripheral stent. It outperformed the Cook Zilver stent in the IMPERIAL Trial presented at TCT 2018.

The Boston Scientific Eluvia self-expanding, drug-eluting peripheral stent. It outperformed the Cook Zilver stent in the IMPERIAL Trial presented at TCT 2018.

Feature | Peripheral Artery Disease (PAD) | January 30, 2019 | Dave Fornell, Editor
In recent years, there has been a lot of focus by vendors on developing better stenting technologies to treat...
Edwards' Sapien 3 Ultra Transcatheter Heart Valve Receives FDA Approval
Technology | Heart Valve Technology | January 02, 2019
January 2, 2019 — Edwards Lifesciences Corp. announced that the Sapien 3 Ultra system has received U.S. Food and Drug...
Sponsored Content | Videos | Cath Lab | November 07, 2018
In 2009, the GuideLiner Catheter revolutionized the concept of guide extension, creating new possibilities in...
Shimadzu Medical Systems Teams With Change Healthcare Cardiology
News | Angiography | October 17, 2018
October 17, 2018 — Shimadzu Medical Systems USA and Change Healthcare have entered a partnership through which Shimadzu...
The cardiovascular innovation cycle presented by TCT Course Director Martin Leon, M.D. at TCT 2018. #TCT2018 #TCT #TCT18

The cardiovascular innovation cycle, presented by TCT Course Director Martin Leon, M.D., at TCT 2018.

Blog | Cath Lab | October 16, 2018
There is a hype cycle surrounding new technologies in all industries, but medicine is unique because of its focus on...

An example of the new transesophageal echo (TEE) visualization technology called TrueVue was shown at TCT 2018 for the first time. Philips’ new photo-realistic rendering is designed to offer a surgical view of cardiac structures to aid transcatheter procedural navigation. The technology also allows the lighting source to be moved around and even behind the anatomy, as demonstrated here. This video, included as part of the most innovative technologies video at TCT 2018, went viral when posted on social media during TCT 2018, and was viewed more than 167,000 times.

Blog | TCT | October 15, 2018
From a cardiovascular device innovation standpoint, the 2018 Transcatheter Cardiovascular Therapeutics (TCT) conference...
Bioresorbable stents (BRS) in development presented by Gregg Stone, M.D., during TCT 2017. Several of the players listed on the slider put their BRS development programs on hold after the negative data from the ABSORB III Trial, but a handful of smaller companies are still pushing the technology forward. #TCT #TCT2018

Bioresorbable stents (BRS) in development, presented by Gregg Stone, M.D., during TCT 2017. Several of the players listed on the slider put their BRS development programs on hold after the negative data from the ABSORB III Trial, but a handful of smaller companies are still pushing the technology forward. (Pghoto by Dave Fornell)

Feature | Stents Bioresorbable | October 12, 2018 | Dave Fornell, Editor
Bioresorbable stent (BRS) technology is not dead, but the unbridled enthusiasm seen two years ago for the technology...
A comparison of target lesion failure (TLF) of the Reva bioresorbable stent to the Absorb and top performing metallic DES. #TCT #TCT2018 #TCT18 #BRS #bioresorbablestents #bioresorbablescaffolds

A comparison of target lesion failure (TLF) of the Reva bioresorbable stent to the Absorb and top performing metallic DES. 

News | Stents Bioresorbable | October 12, 2018
October 12, 2018 – Reva Medical presented four key data sets demonstrating the capabilities of the company’s Fantom...
Videos | October 11, 2018
Professor Ian Meredith, MBBS, Ph.D., global chief medical officer and executive vice president, Boston Scientific,...
Videos | October 11, 2018
A discussion with Professor Ian Meredith, MBBS, Ph.D., global chief medical officer and executive vice president,...